Professional Documents
Culture Documents
When Supply Is of Public Interest Roche and Tamiflu
When Supply Is of Public Interest Roche and Tamiflu
Background
Tamiflu in 2005
Capacity management issues
Response and improvements
Tamiflu in 2007
Going forward
BACKGROUND
Shikimic Acid
Step 1
Epoxide
Step 2
6 months
Azide
Step 3
internal
internal
internal
internal
internal
Stock
5 5 5 5 30 60
= = 18.5 %
30 20 35 10 15 20 35 10 15 30 270
KEY PERFORMANCE INDICATOR (2005)
KPI 2005
Limited capacity
Issues
Logistic
Government assurance
Increase production
capacity up to 400 m in
18 months
Redesign Sublicensing
Development Process
Focused production
Building New Plants
Expand supply network
PROCESS MAPPING (2007)
Strong Custom
Suppliers Demand Forecast er/Govt
50% (Ongoing Process) Demand
(+20%)
Step 1 Step 2 Step 3 Step 4 Step 5
internal
Order
internal
internal
internal
internal
internal
Stock
internal
internal
10 5 10 5 10 40
= = 25.8 %
10 10 20 5 15 10 15 10 10 10 155
KPI - 2005 vs 2007
Investors Media
?
SCENARIO ANALYSIS
Forecasted demand is 30
million
Sublicensing to India
and China
Invest in R&D
No immediate/low
risk of pandemic
Plan C Technology Transfer
Improved capability to
respond to pandemic